Skip to main content

Advertisement

Table 1 Clinical characteristics before ASCT

From: The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016

Characteristic N Per cent OS 100 days NRM 100 days
433 100% OR (95% CI) p OR (95% CI) p
Years of age, median (range; p10; p90): 56 (18–72; 35; 67)
 18–45 105 24   0.28   0.29
 46–55 98 23     
 56–65 165 38     
 66–72 65 15     
Female sex 151 35   0.39   0.26
ASCT year
 1994–1999 42 10   0.43   0.25
 2000–2009 161 37     
 2010–2016 230 53     
Indication for ASCT
 Planned upfront 155 36   0.054   0.053
 Relapsed/refractory 278 64     
Years since lymphoma diagnosis, median (range): 1.2 (0.2–22.6)     0.45   0.40
Number of prior lines of therapy
 1 161 40   0.16   0.20
 2 201 50     
 ≥ 3 44 11     
Days between date of last chemotherapy and date of ASCT, median (range; p10; p90): 35 (20–415; 27; 53)
 < 28 54 14   0.79   0.48
 28–34 135 34     
 35–41 113 28     
 42–55 63 16     
 ≥ 56 33 8     
Prior rituximab 263 61   0.069   0.12
Prior fludarabine 26 6   0.91   0.72
ASCT in poor remission 70 16   0.32   0.90
Harvested CD34+ cells/kg, median (range; p10; p90): 6.2 (1.0–48.0; 3.4; 13.7)
 1.0–3.9 million 59 14 2.0 (0.7–6.2) 0.040 3.4 (1.0–11.4) 0.040
 4.0–4.9 million 50 12 4.2 (1.6–11.2)   5.2 (1.6–16.9)  
 5.0–9.9 million 228 54 1   1  
 10.0–48.0 million 82 20 1.4 (0.5–4.3)   1.9 (0.5–6.9)  
 < 5 vs ≥ 5 million    3.1 (1.5–6.5) 0.003 4.0 (1.7–9.4) 0.001
Stem cell source       
 Peripheral blood 424 98 1 0.008 1 0.002
 Bone marrow 9 2 7.1 (1.7–29.8)   9.4 (2.2–40.3)  
Leukocytes per nL, median (range; p10, p90): 4.1 (1.0–25.9; 2.2; 7.2)
 Normal or high (≥ 3.5) 271 65   0.062   0.059
Neutrophils per nL, median (range; p10; p90): 2.4 (< 0.2–45.0; 1.0; 5.1)
 Normal or high (≥ 1.5) 246 76   0.13   0.26
Lymphocytes per nL, median (range; p10; p90): 0.8 (0.3–8.3; 0.4; 1.9)
 Normal or high (≥ 1.0) 65 37   0.65   0.40
Platelets per nL, median (range; p10; p90): 199 (7–1395; 105; 363)
 Low (< 150) 114 27 3.2 (1.5–6.6) 0.002 4.9 (2.1–11.7) 0.0003
Haemoglobin in g/L, median (range; p10; p90): 105 (75–150; 91; 123)
 Low (< 120) 364 87   0.25   0.45
Creatinine in multiples of UNL, median (range; p10; p90): 0.74 (0.29–1.90; 0.58; 1.02)
 Elevated (≥ UNL) 50 12 2.8 (1.2–6.8) 0.018 4.1 (1.6–10.1) 0.002
Albumin in g/L, median (range; p10; p90): 37 (14–44; 32; 41)
 Low (< 36) 102 26 2.6 (1.2–5.7) 0.016 3.2 (1.3–7.9) 0.013
C-reactive protein in mg/L, median (range; p10; p90): 2 (0–169; 0; 20)
 < 3 160 50 1 0.0006 1 0.0013
 3–9 83 26 5.6 (1.4–21.6)   6.3 (1.2–31.9)  
 ≥ 10 75 24 9.0 (2.4–33.3)   11.0 (2.3–52.5)  
Conditioning       
 BEAM 403 93   0.61   0.80
 BEAC 22 5     
 BCNU-thiotepa 7 2     
 Cy-TBI 1 0     
Given dose of CD34+ cells/kg, median (range; p10; p90): 6.0 (1.0–48.0; 3.4; 11.4)
 1.0–3.9 million 61 15   0.087   0.071
 4.0–4.9 million 58 14     
 5.0–9.9 million 233 56     
 10.0–48.0 million 66 16     
Tandem-treatment after ASCT 45 10   1.0   1.0
 Local irradiation 22 5     
 Splenectomy 2 0     
 Temozolomide maintenance 18 4     
 Allogeneic SCT 3 1     
  1. OS, overall survival; NLM, non-lymphoma mortality; ASCT, autologous stem-cell transplantation; UNL, upper normal limit; HR, hazard ratio; CI, confidence interval; OR, odds ratio